Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Mol Cancer Res. 2021 Aug;19(8):1308-1321. doi: 10.1158/1541-7786.MCR-20-0884. Epub 2021 Apr 21.
The incidence of anal squamous cell carcinoma (ASCC) has been increasing, particularly in populations with HIV. Human papillomavirus (HPV) is the causal factor in 85% to 90% of ASCCs, but few studies evaluated HPV genotypes and integrations in relation to genomic alterations in ASCC. Using whole-exome sequence data for primary ( = 56) and recurrent ( = 31) ASCC from 72 patients, we detected HPV DNA in 87.5% of ASCC, of which HPV-16, HPV-18, and HPV-6 were detected in 56%, 22%, and 33% of HIV-positive ( = 9) compared with 83%, 3.2%, and 1.6% of HIV-negative cases ( = 63), respectively. Recurrent copy-number variations (CNV) involving genes with documented roles in cancer included amplification of PI3KCA and deletion of APC in primary and recurrent tumors; amplifications of CCND1, MYC, and NOTCH1 and deletions of BRCA2 and RB1 in primary tumors; and deletions of ATR, FANCD2, and FHIT in recurrent tumors. DNA damage response genes were enriched among recurrently deleted genes in recurrent ASCCs ( = 0.001). HPV integrations were detected in 29 of 76 (38%) ASCCs and were more frequent in stage III-IV versus stage I-II tumors. HPV integrations were detected near MYC and CCND1 amplifications and recurrent targets included NFI and MUC genes. These results suggest HPV genotypes in ASCC differ by HIV status, HPV integration is associated with ASCC progression, and DNA damage response genes are commonly disrupted in recurrent ASCCs. IMPLICATIONS: These data provide the largest whole-exome sequencing study of the ASCC genomic landscape to date and identify HPV genotypes, integrations, and recurrent CNVs in primary or recurrent ASCCs.
肛门鳞状细胞癌 (ASCC) 的发病率一直在上升,尤其是在 HIV 感染者中。人乳头瘤病毒 (HPV) 是 85%至 90%的 ASCC 的致病因素,但很少有研究评估 HPV 基因型和整合与 ASCC 的基因组改变之间的关系。我们使用来自 72 名患者的原发性 ( = 56) 和复发性 ( = 31) ASCC 的全外显子组序列数据,在 87.5%的 ASCC 中检测到 HPV DNA,其中 HPV-16、HPV-18 和 HPV-6 在 56%、22%和 33%的 HIV 阳性患者中检出( = 9),而在 83%、3.2%和 1.6%的 HIV 阴性患者中检出( = 63)。涉及已证实与癌症相关的基因的复发性拷贝数变异 (CNV) 包括原发性和复发性肿瘤中 PI3KCA 的扩增和 APC 的缺失;原发性肿瘤中 CCND1、MYC 和 NOTCH1 的扩增以及 BRCA2 和 RB1 的缺失;以及复发性肿瘤中 ATR、FANCD2 和 FHIT 的缺失。在复发性 ASCC 中,DNA 损伤反应基因在复发性缺失基因中富集( = 0.001)。在 76 例 ASCC 中有 29 例 (38%)检测到 HPV 整合,在 III-IV 期与 I-II 期肿瘤中更常见。HPV 整合发生在 MYC 和 CCND1 扩增附近,且复发性靶点包括 NFI 和 MUC 基因。这些结果表明,ASCC 中的 HPV 基因型因 HIV 状态而异,HPV 整合与 ASCC 进展相关,且 DNA 损伤反应基因在复发性 ASCC 中经常被破坏。意义:这些数据提供了迄今为止对 ASCC 基因组图谱进行的最大全外显子组测序研究,并确定了原发性或复发性 ASCC 中的 HPV 基因型、整合和复发性 CNV。